Clinical Development

  Clinical Development / About Type 1 Diabetes

About Type 1 Diabetes

Type 1 diabetes (T1D) is a chronic autoimmune disease in which the immune system's T cells mistakenly attack the body's own insulin-producing beta cells, leaving the body unable to produce insulin, a hormone necessary for the body to provide energy. People living with T1D are dependent on insulin, administered via injection or pump, to survive.
Managing type 1 diabetes requires a strict regimen of insulin and food intake, exercise, and other activities. There is no cure for type 1 diabetes, and over time it can lead to serious complications including stroke, heart disease, kidney disease and amputation.

  • > Approximately 1.25 million American children and adults have type 1 diabetes1, and 5 million are expected to have T1D by 2050
  • > 40,000 people are diagnosed each year in the U.S.
  • > Between 2001 and 2009, there was a 21 percent increase in the prevalence of T1D in people under age 20
  • > Less than one-third of people with T1D in the U.S. are consistently achieving target blood-glucose control levels

Type 1 diabetes and celiac disease are both autoimmune disorders linked to the human leukocyte antigen (HLA) gene complex and approximately 8% of people living with celiac disease also live with type 1 diabetes1.

ImmusanT is rapidly advancing the development of a therapeutic vaccine for type 1 diabetes and has received support from the JDRF T1D Fund. To view ImmusanT’s list of programs, please visit the pipeline page.

  1. Cohn A, Sofia MA, Kupfer SS. Type 1 Diabetes and Celiac Disease: Clinical Overlap and New Insights into Disease Pathogenesis. Current Diabetes Reports. 2014.